Clinical trials

The goal of this clinical trial is to evaluate the dermatological safety and acceptability of a cosmetic product in participants with sensitive skin. The main questions it aims to answer are: * Does the investigational product demonstrate dermatological acceptability in participants with sensitive skin under normal conditions of use? * Does the investigational product present a low risk of skin irritation? * What discomfort sensations, if any, are reported by participants with sensitive skin during product use? Participants will: * Apply the investigational product to the face and body twice daily under normal conditions of use. * Undergo clinical dermatological evaluations to assess signs of irritation and product tolerability. * Report any discomfort sensations experienced during the study period. The study will enroll 33 healthy male and female participants aged 18 years or older with sensitive skin confirmed by a positive Stinging Test. This is a single-center, single-blind clinical trial designed to evaluate the dermatological safety of the investigational product through clinical dermatological assessments under real-world conditions of use.

The goal of this clinical trial is to evaluate the dermatological and ophthalmological safety of a cosmetic product and to assess its comedogenic and acnegenic potential in participants with oily or acne-prone skin. The main questions it aims to answer are: * Does the investigational product demonstrate an absence of comedogenic potential under normal conditions of use? * Does the investigational product demonstrate an absence of acnegenic potential under normal conditions of use? * Does the investigational product demonstrate dermatological and ophthalmological acceptability? * Does the investigational product present a low risk of irritation or discomfort during the study period? Participants will: * Apply the investigational cosmetic product to the face and body twice daily for 28 days. * Undergo dermatological evaluations to assess skin tolerability and identify any signs of irritation or adverse reactions. * Undergo ophthalmological evaluations to assess ocular tolerability. * Undergo clinical assessments to evaluate the comedogenic and acnegenic potential of the investigational product. The study will enroll 33 male and female participants aged 18 to 45 years with oily or acne-prone skin. Participants will be followed for 28 days while using the investigational product according to the study protocol.

The goal of this clinical trial is to evaluate the dermatological safety and acceptability of a cosmetic product in healthy pediatric participants. The main questions it aims to answer are: * Does the investigational product demonstrate pediatric acceptability under normal conditions of use? * Does the investigational product present a low risk of skin irritation in the pediatric population? * Are any discomfort sensations reported during product use? Participants will: * Apply the investigational product to the face and body twice daily for 21 days. * Undergo clinical evaluations to assess skin tolerability and identify any signs of irritation or adverse reactions. * Be monitored for potential discomfort sensations throughout the study period. The study will enroll 33 healthy male and female participants aged from 7 days to 14 years. This is a single-center, single-blind clinical trial designed to evaluate the safety of the investigational product through clinical assessments under normal conditions of use.

The goal of this clinical trial is to evaluate the dermatological safety and efficacy of a moisturizing product in participants with moderate to severe xerosis of the lower limbs. The main questions it aims to answer are: * Does the investigational product demonstrate dermatological acceptability and absence of irritation under real-world conditions of use? * Does the investigational product improve skin hydration after single and repeated applications? * Does the investigational product improve skin barrier recovery and strengthen skin barrier function? * How do participants perceive the performance and efficacy of the investigational product? Participants will: * Apply the investigational moisturizing product twice daily for 28 days. * Undergo clinical dermatological evaluations to assess skin tolerability and potential irritation. * Undergo instrumental assessments of skin hydration using a Corneometer® and skin barrier function using a Tewameter®. * Complete questionnaires regarding product performance and perceived efficacy. The study will enroll 22 male and female participants aged 35 to 65 years with clinically confirmed moderate to severe xerosis of the lower limbs.

This is a single-center, single-blind clinical study designed to evaluate the efficacy of a depigmenting gel cream through clinical, subjective, and instrumental assessments. A total of 40 female participants, aged 30 to 60 years, will be enrolled and followed for 90 days while using the study product.Participants will be assigned to one of two groups. Group I will include 20 participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, representing Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Group II will include 20 participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), representing Fitzpatrick skin phototypes II to V. The study aims to evaluate the product's effectiveness in reducing facial hyperpigmentation and improving skin appearance over the treatment period.

This is a single-center, single-blind clinical study designed to evaluate the dermatological safety of a cosmetic product and to demonstrate the absence of comedogenic and acnegenic potential. A total of 33 female participants, aged 18 to 60 years, with oily and acne-prone skin will be enrolled. Participants will use the investigational product for 28 days under normal conditions of use. Dermatological safety, skin tolerability, and the absence of comedogenic and acnegenic effects will be assessed throughout the study period by clinical evaluations conducted according to the study protocol.

This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.